TC PMY 123
Alternative Names: TC PMY123Latest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Unknown
- Developer Pulmonomy
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cryptococcosis
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Cryptococcosis in USA (Inhalation, Powder)
- 12 Mar 2020 Preclinical trials in Cryptococcosis in USA (Inhalation) before March 2020 (Pulmonomy's pipeline, March 2020)